CN105764515B - 对胰腺癌的治疗 - Google Patents

对胰腺癌的治疗 Download PDF

Info

Publication number
CN105764515B
CN105764515B CN201480064033.0A CN201480064033A CN105764515B CN 105764515 B CN105764515 B CN 105764515B CN 201480064033 A CN201480064033 A CN 201480064033A CN 105764515 B CN105764515 B CN 105764515B
Authority
CN
China
Prior art keywords
tumor
compound
cancer
pancreatic cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480064033.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105764515A (zh
Inventor
D·W·赫德尔
I·洛塞
J·M·玛森
M·R·布雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of CN105764515A publication Critical patent/CN105764515A/zh
Application granted granted Critical
Publication of CN105764515B publication Critical patent/CN105764515B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480064033.0A 2013-10-18 2014-10-03 对胰腺癌的治疗 Expired - Fee Related CN105764515B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361892887P 2013-10-18 2013-10-18
US61/892,887 2013-10-18
PCT/CA2014/050952 WO2015054781A1 (en) 2013-10-18 2014-10-03 Treatment for pancreatic cancer

Publications (2)

Publication Number Publication Date
CN105764515A CN105764515A (zh) 2016-07-13
CN105764515B true CN105764515B (zh) 2020-02-28

Family

ID=52827497

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480064033.0A Expired - Fee Related CN105764515B (zh) 2013-10-18 2014-10-03 对胰腺癌的治疗

Country Status (13)

Country Link
US (1) US9642856B2 (enExample)
EP (1) EP3057593B1 (enExample)
JP (1) JP6525983B2 (enExample)
KR (1) KR102195494B1 (enExample)
CN (1) CN105764515B (enExample)
AU (1) AU2014336917B2 (enExample)
CA (1) CA2927612C (enExample)
EA (1) EA030089B1 (enExample)
ES (1) ES2908200T3 (enExample)
IL (1) IL245037B (enExample)
MX (1) MX357763B (enExample)
SG (1) SG11201602882VA (enExample)
WO (1) WO2015054781A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
NZ602350A (en) 2010-04-06 2014-05-30 Univ Health Network Kinase inhibitors and method of treating cancer with same
SI3057965T1 (sl) 2013-10-18 2019-04-30 University Health Network Sol in kristalne oblike inhibitorja PLK-4
CA3074876A1 (en) * 2017-09-08 2019-03-14 University Health Network Combination therapies for inhibition of polo-like kinase 4
BR112021021106A2 (pt) 2019-04-24 2021-12-14 Univ Health Network Forma cristalina s4 do inibidor plk4 fumarato (ir,2s)-(e)-2-(3-(4-((cis-2,6-dimetilmorfolino)metil)estiril)-1h-imidazol-6-il)-5'-metoxiespiro[ciclopropano-1,3'-indolin]-2'ona
US20240270722A1 (en) 2021-05-11 2024-08-15 Oric Pharmaceuticals, Inc. Polo like kinase 4 inhibitors
CN115677682B (zh) * 2021-07-30 2023-07-18 上海齐鲁制药研究中心有限公司 螺环类plk4抑制剂及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892766A (zh) * 2010-04-06 2013-01-23 大学健康网络 激酶抑制剂和用其治疗癌症的方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US5182397A (en) 1990-05-31 1993-01-26 American Cyanamid Company Aryloxyspiroalkylindolinone herbicides
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
ATE308520T1 (de) 1996-08-23 2005-11-15 Sugen Inc Kombinatorische bibliotheken von indolinone und verwandte produkte und verfahren zur behandlung von krankheiten
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
CA2383623A1 (en) 1998-08-04 2000-02-17 Sugen, Inc. 3-methylidenyl-2-indolinone modulators of protein kinase
EP1165513A1 (en) 1999-03-24 2002-01-02 Sugen, Inc. Indolinone compounds as kinase inhibitors
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
US7205328B2 (en) 2002-10-21 2007-04-17 Irm Llc Oxindoles with anti-HIV activity
WO2005058309A1 (en) 2003-12-16 2005-06-30 Leo Pharma A/S Novel therapeutic use of indolinone derivatives
US7309787B2 (en) 2005-07-13 2007-12-18 Allergan, Inc. Kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
US20070135509A1 (en) 2005-12-09 2007-06-14 Blackburn Thomas P Indolone compounds useful to treat cognitive impairment
US20090209537A1 (en) * 2006-06-30 2009-08-20 Kyowa Hakko Kirin Co., Ltd. Aurora inhibitors
WO2008152014A2 (en) 2007-06-12 2008-12-18 Boehringer Ingelheim International Gmbh 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases
AU2008340991B2 (en) 2007-12-21 2012-02-23 University Health Network Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer
JP2009173629A (ja) 2007-12-21 2009-08-06 Banyu Pharmaceut Co Ltd Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体
EP2262499B1 (en) 2008-03-11 2016-12-21 University Health Network Mk-0557 for use in the treatment of cancer
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
DE102008040187A1 (de) 2008-07-04 2010-01-07 Robert Bosch Gmbh Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung
ES2465971T3 (es) 2009-04-06 2014-06-09 University Health Network Inhibidores de quinasa y método para tratar cáncer con los mismos
WO2011069298A1 (en) 2009-12-11 2011-06-16 F. Hoffmann-La Roche Ag Novel cyclopropane indolinone derivatives
JP5056876B2 (ja) 2010-03-19 2012-10-24 Ｊｆｅスチール株式会社 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法
EP2588110B1 (en) 2010-07-02 2018-10-17 University Health Network Methods of targeting pten mutant diseases and compositions therefor
WO2012048411A1 (en) 2010-10-13 2012-04-19 University Health Network Plk-4 inhibitors and method of treating cancer with same
JP2014511389A (ja) 2011-02-28 2014-05-15 エピザイム インコーポレイテッド 置換６，５−縮合二環式ヘテロアリール化合物
CA3101968A1 (en) 2017-06-29 2019-01-03 Quanticision Diagnostics Canada, Inc. Apparatus and method for absolute quantification of biomarkers for solid tumor diagnosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102892766A (zh) * 2010-04-06 2013-01-23 大学健康网络 激酶抑制剂和用其治疗癌症的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells;Steven L. Warner等;《Mol Cancer Ther》;20061031;第5卷(第10期);第2450-2458页 *
Polo-like kinase 4 (Plk4) promotes cancer cell invasion;Kazazian K等;《Journal of the American College of Surgeons》;20130930;第217卷(第3期);第S128页 *

Also Published As

Publication number Publication date
IL245037B (en) 2019-06-30
KR102195494B1 (ko) 2020-12-28
SG11201602882VA (en) 2016-05-30
JP2016533373A (ja) 2016-10-27
AU2014336917A1 (en) 2016-05-05
US9642856B2 (en) 2017-05-09
CA2927612A1 (en) 2015-04-23
EA030089B1 (ru) 2018-06-29
AU2014336917B2 (en) 2018-11-29
JP6525983B2 (ja) 2019-06-05
ES2908200T3 (es) 2022-04-28
MX357763B (es) 2018-07-23
WO2015054781A1 (en) 2015-04-23
EP3057593A1 (en) 2016-08-24
US20160250220A1 (en) 2016-09-01
EA201690763A1 (ru) 2016-09-30
CN105764515A (zh) 2016-07-13
CA2927612C (en) 2022-08-30
EP3057593B1 (en) 2021-12-08
MX2016004967A (es) 2016-11-18
NZ718923A (en) 2021-11-26
KR20160062176A (ko) 2016-06-01
EP3057593A4 (en) 2017-03-08
IL245037A0 (en) 2016-05-31

Similar Documents

Publication Publication Date Title
CN105764515B (zh) 对胰腺癌的治疗
KR102713072B1 (ko) 두경부암 치료를 위한 egfr 저해제
EP3638233B1 (en) Tinostamustine for use in treating ovarian cancer
CN112807434B (zh) Perk抑制剂在制备肝癌药物的增效剂中的应用
KR20190025733A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
EP4119557A1 (en) Pharmaceutical combination comprising pyridino[1,2-a]pyrimidinone compound
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
CN115038447A (zh) 用于治疗癌症的组合疗法
JP6630285B2 (ja) Ｅｒｇ発癌遺伝子陽性癌のための新規阻害剤
US20210046106A1 (en) Methods of treating cancer with androgen deprivation therapy in combination with an inhibitor of the sp1 transcription factor
HK1227304B (en) Treatment for pancreatic cancer
HK1227304A1 (en) Treatment for pancreatic cancer
NZ718923B2 (en) Treatment for pancreatic cancer
CN107137403B (zh) 一种pi3k/mtor抑制剂在制备治疗胰腺癌的药物中的用途
CN117398385A (zh) 用于抑制癌症转移及治疗的组合物
CN114617969A (zh) 乐伐替尼和Aurora-A激酶抑制剂在制备抑制癌症的药物中的应用
HK40006321B (en) Cortexolone 17alpha-valerate for use in the treatment of tumours
US20210355223A1 (en) Combinations for Treating Cancer
AU2015200149A1 (en) Novel antitumoral use of cabazitaxel

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200228